Account-creators
1,040
edits
Difference between revisions of "Neurodegenerative diseases"
Jump to navigation
Jump to search
Neurodegenerative diseases (view source)
Revision as of 06:47, 24 October 2019
, 06:47, 24 October 2019→Clinical perspective: poor correlations
Jensflorian (talk | contribs) (→Clinical perspective: Poor clinical - molecular correlations) |
Jensflorian (talk | contribs) (→Clinical perspective: poor correlations) |
||
| Line 201: | Line 201: | ||
=Clinical perspective= | =Clinical perspective= | ||
*Correlations between clinical signs and molecular can be poor. | *Correlations between clinical signs and molecular can be poor. | ||
**Example: The MAPT A152T gene mutation in the MAPT gene may cause clinical symptoms matching AD, [[Neurodegenerative diseases#Corticobasal degeneration|CBD]], [[Neurodegenerative diseases#Progressive supranuclear palys|PSP]] and [[Neurodegenerative diseases#Lewy body disease|LBD]]. | **Example: The MAPT A152T gene mutation in the MAPT gene may cause clinical symptoms matching AD, [[Neurodegenerative diseases#Corticobasal degeneration|CBD]], [[Neurodegenerative diseases#Progressive supranuclear palys|PSP]] and [[Neurodegenerative diseases#Lewy body disease|LBD]].<ref>{{Cite journal | last1 = Coppola | first1 = G. | last2 = Chinnathambi | first2 = S. | last3 = Lee | first3 = JJ. | last4 = Dombroski | first4 = BA. | last5 = Baker | first5 = MC. | last6 = Soto-Ortolaza | first6 = AI. | last7 = Lee | first7 = SE. | last8 = Klein | first8 = E. | last9 = Huang | first9 = AY. | title = Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. | journal = Hum Mol Genet | volume = 21 | issue = 15 | pages = 3500-12 | month = Aug | year = 2012 | doi = 10.1093/hmg/dds161 | PMID = 22556362 }}</ref> | ||
===Dementia general (mostly useless) DDx=== | ===Dementia general (mostly useless) DDx=== | ||